Pharma & Healthcare
Global Kidney Cancer Medicine Market Research Report 2025
- Jul 10, 25
- ID: 367471
- Pages: 92
- Figures: 94
- Views: 2
The global market for Kidney Cancer Medicine was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Kidney cancer -- also called renal cancer -- is a disease in which kidney cells become malignant (cancerous) and grow out of control, forming a tumor. Almost all kidney cancers first appear in the lining of tiny tubes (tubules) in the kidney. This type of kidney cancer is called renal cell carcinoma.
Renal cell carcinoma (RCC) is a common malignant tumor worldwide, referred to as kidney cancer. According to the World Health Organization, the global incidence of kidney cancer accounts for 2% to 3% of systemic tumors. Among malignant tumors of the urinary system, its incidence is second only to bladder cancer, and it is increasing year by year. In recent years, targeted therapy and precision therapy have become standard treatments for kidney cancer.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Kidney Cancer Medicine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Kidney Cancer Medicine.
The Kidney Cancer Medicine market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Kidney Cancer Medicine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Kidney Cancer Medicine companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Pfizer
Bristol-Myers Squibb
Roche
GSK
Novartis
Bayer
Merck & Co.
Exelixis
Takeda
Eisai
CTTQ
AVEO Oncology
Everest Pharm
Cipla
NATCO
Beacon Pharma
SAMARTH
Segment by Type
Monoclonal Antibody
mTOR Inhibitors
Kinase Inhibitors
Other
Segment by Application
Renal Cell Carcinoma (RCC)
Transitional Cell Carcinoma (TCC)
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Kidney Cancer Medicine company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Kidney cancer -- also called renal cancer -- is a disease in which kidney cells become malignant (cancerous) and grow out of control, forming a tumor. Almost all kidney cancers first appear in the lining of tiny tubes (tubules) in the kidney. This type of kidney cancer is called renal cell carcinoma.
Renal cell carcinoma (RCC) is a common malignant tumor worldwide, referred to as kidney cancer. According to the World Health Organization, the global incidence of kidney cancer accounts for 2% to 3% of systemic tumors. Among malignant tumors of the urinary system, its incidence is second only to bladder cancer, and it is increasing year by year. In recent years, targeted therapy and precision therapy have become standard treatments for kidney cancer.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Kidney Cancer Medicine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Kidney Cancer Medicine.
The Kidney Cancer Medicine market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Kidney Cancer Medicine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Kidney Cancer Medicine companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Pfizer
Bristol-Myers Squibb
Roche
GSK
Novartis
Bayer
Merck & Co.
Exelixis
Takeda
Eisai
CTTQ
AVEO Oncology
Everest Pharm
Cipla
NATCO
Beacon Pharma
SAMARTH
Segment by Type
Monoclonal Antibody
mTOR Inhibitors
Kinase Inhibitors
Other
Segment by Application
Renal Cell Carcinoma (RCC)
Transitional Cell Carcinoma (TCC)
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Kidney Cancer Medicine company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Kidney Cancer Medicine Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Monoclonal Antibody
1.2.3 mTOR Inhibitors
1.2.4 Kinase Inhibitors
1.2.5 Other
1.3 Market by Application
1.3.1 Global Kidney Cancer Medicine Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Renal Cell Carcinoma (RCC)
1.3.3 Transitional Cell Carcinoma (TCC)
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Kidney Cancer Medicine Market Perspective (2020-2031)
2.2 Global Kidney Cancer Medicine Growth Trends by Region
2.2.1 Global Kidney Cancer Medicine Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Kidney Cancer Medicine Historic Market Size by Region (2020-2025)
2.2.3 Kidney Cancer Medicine Forecasted Market Size by Region (2026-2031)
2.3 Kidney Cancer Medicine Market Dynamics
2.3.1 Kidney Cancer Medicine Industry Trends
2.3.2 Kidney Cancer Medicine Market Drivers
2.3.3 Kidney Cancer Medicine Market Challenges
2.3.4 Kidney Cancer Medicine Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Kidney Cancer Medicine Players by Revenue
3.1.1 Global Top Kidney Cancer Medicine Players by Revenue (2020-2025)
3.1.2 Global Kidney Cancer Medicine Revenue Market Share by Players (2020-2025)
3.2 Global Kidney Cancer Medicine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Kidney Cancer Medicine Revenue
3.4 Global Kidney Cancer Medicine Market Concentration Ratio
3.4.1 Global Kidney Cancer Medicine Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Kidney Cancer Medicine Revenue in 2024
3.5 Global Key Players of Kidney Cancer Medicine Head office and Area Served
3.6 Global Key Players of Kidney Cancer Medicine, Product and Application
3.7 Global Key Players of Kidney Cancer Medicine, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Kidney Cancer Medicine Breakdown Data by Type
4.1 Global Kidney Cancer Medicine Historic Market Size by Type (2020-2025)
4.2 Global Kidney Cancer Medicine Forecasted Market Size by Type (2026-2031)
5 Kidney Cancer Medicine Breakdown Data by Application
5.1 Global Kidney Cancer Medicine Historic Market Size by Application (2020-2025)
5.2 Global Kidney Cancer Medicine Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Kidney Cancer Medicine Market Size (2020-2031)
6.2 North America Kidney Cancer Medicine Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Kidney Cancer Medicine Market Size by Country (2020-2025)
6.4 North America Kidney Cancer Medicine Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Kidney Cancer Medicine Market Size (2020-2031)
7.2 Europe Kidney Cancer Medicine Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Kidney Cancer Medicine Market Size by Country (2020-2025)
7.4 Europe Kidney Cancer Medicine Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Kidney Cancer Medicine Market Size (2020-2031)
8.2 Asia-Pacific Kidney Cancer Medicine Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Kidney Cancer Medicine Market Size by Region (2020-2025)
8.4 Asia-Pacific Kidney Cancer Medicine Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Kidney Cancer Medicine Market Size (2020-2031)
9.2 Latin America Kidney Cancer Medicine Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Kidney Cancer Medicine Market Size by Country (2020-2025)
9.4 Latin America Kidney Cancer Medicine Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Kidney Cancer Medicine Market Size (2020-2031)
10.2 Middle East & Africa Kidney Cancer Medicine Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Kidney Cancer Medicine Market Size by Country (2020-2025)
10.4 Middle East & Africa Kidney Cancer Medicine Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Pfizer
11.1.1 Pfizer Company Details
11.1.2 Pfizer Business Overview
11.1.3 Pfizer Kidney Cancer Medicine Introduction
11.1.4 Pfizer Revenue in Kidney Cancer Medicine Business (2020-2025)
11.1.5 Pfizer Recent Development
11.2 Bristol-Myers Squibb
11.2.1 Bristol-Myers Squibb Company Details
11.2.2 Bristol-Myers Squibb Business Overview
11.2.3 Bristol-Myers Squibb Kidney Cancer Medicine Introduction
11.2.4 Bristol-Myers Squibb Revenue in Kidney Cancer Medicine Business (2020-2025)
11.2.5 Bristol-Myers Squibb Recent Development
11.3 Roche
11.3.1 Roche Company Details
11.3.2 Roche Business Overview
11.3.3 Roche Kidney Cancer Medicine Introduction
11.3.4 Roche Revenue in Kidney Cancer Medicine Business (2020-2025)
11.3.5 Roche Recent Development
11.4 GSK
11.4.1 GSK Company Details
11.4.2 GSK Business Overview
11.4.3 GSK Kidney Cancer Medicine Introduction
11.4.4 GSK Revenue in Kidney Cancer Medicine Business (2020-2025)
11.4.5 GSK Recent Development
11.5 Novartis
11.5.1 Novartis Company Details
11.5.2 Novartis Business Overview
11.5.3 Novartis Kidney Cancer Medicine Introduction
11.5.4 Novartis Revenue in Kidney Cancer Medicine Business (2020-2025)
11.5.5 Novartis Recent Development
11.6 Bayer
11.6.1 Bayer Company Details
11.6.2 Bayer Business Overview
11.6.3 Bayer Kidney Cancer Medicine Introduction
11.6.4 Bayer Revenue in Kidney Cancer Medicine Business (2020-2025)
11.6.5 Bayer Recent Development
11.7 Merck & Co.
11.7.1 Merck & Co. Company Details
11.7.2 Merck & Co. Business Overview
11.7.3 Merck & Co. Kidney Cancer Medicine Introduction
11.7.4 Merck & Co. Revenue in Kidney Cancer Medicine Business (2020-2025)
11.7.5 Merck & Co. Recent Development
11.8 Exelixis
11.8.1 Exelixis Company Details
11.8.2 Exelixis Business Overview
11.8.3 Exelixis Kidney Cancer Medicine Introduction
11.8.4 Exelixis Revenue in Kidney Cancer Medicine Business (2020-2025)
11.8.5 Exelixis Recent Development
11.9 Takeda
11.9.1 Takeda Company Details
11.9.2 Takeda Business Overview
11.9.3 Takeda Kidney Cancer Medicine Introduction
11.9.4 Takeda Revenue in Kidney Cancer Medicine Business (2020-2025)
11.9.5 Takeda Recent Development
11.10 Eisai
11.10.1 Eisai Company Details
11.10.2 Eisai Business Overview
11.10.3 Eisai Kidney Cancer Medicine Introduction
11.10.4 Eisai Revenue in Kidney Cancer Medicine Business (2020-2025)
11.10.5 Eisai Recent Development
11.11 CTTQ
11.11.1 CTTQ Company Details
11.11.2 CTTQ Business Overview
11.11.3 CTTQ Kidney Cancer Medicine Introduction
11.11.4 CTTQ Revenue in Kidney Cancer Medicine Business (2020-2025)
11.11.5 CTTQ Recent Development
11.12 AVEO Oncology
11.12.1 AVEO Oncology Company Details
11.12.2 AVEO Oncology Business Overview
11.12.3 AVEO Oncology Kidney Cancer Medicine Introduction
11.12.4 AVEO Oncology Revenue in Kidney Cancer Medicine Business (2020-2025)
11.12.5 AVEO Oncology Recent Development
11.13 Everest Pharm
11.13.1 Everest Pharm Company Details
11.13.2 Everest Pharm Business Overview
11.13.3 Everest Pharm Kidney Cancer Medicine Introduction
11.13.4 Everest Pharm Revenue in Kidney Cancer Medicine Business (2020-2025)
11.13.5 Everest Pharm Recent Development
11.14 Cipla
11.14.1 Cipla Company Details
11.14.2 Cipla Business Overview
11.14.3 Cipla Kidney Cancer Medicine Introduction
11.14.4 Cipla Revenue in Kidney Cancer Medicine Business (2020-2025)
11.14.5 Cipla Recent Development
11.15 NATCO
11.15.1 NATCO Company Details
11.15.2 NATCO Business Overview
11.15.3 NATCO Kidney Cancer Medicine Introduction
11.15.4 NATCO Revenue in Kidney Cancer Medicine Business (2020-2025)
11.15.5 NATCO Recent Development
11.16 Beacon Pharma
11.16.1 Beacon Pharma Company Details
11.16.2 Beacon Pharma Business Overview
11.16.3 Beacon Pharma Kidney Cancer Medicine Introduction
11.16.4 Beacon Pharma Revenue in Kidney Cancer Medicine Business (2020-2025)
11.16.5 Beacon Pharma Recent Development
11.17 SAMARTH
11.17.1 SAMARTH Company Details
11.17.2 SAMARTH Business Overview
11.17.3 SAMARTH Kidney Cancer Medicine Introduction
11.17.4 SAMARTH Revenue in Kidney Cancer Medicine Business (2020-2025)
11.17.5 SAMARTH Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Kidney Cancer Medicine Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Monoclonal Antibody
1.2.3 mTOR Inhibitors
1.2.4 Kinase Inhibitors
1.2.5 Other
1.3 Market by Application
1.3.1 Global Kidney Cancer Medicine Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Renal Cell Carcinoma (RCC)
1.3.3 Transitional Cell Carcinoma (TCC)
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Kidney Cancer Medicine Market Perspective (2020-2031)
2.2 Global Kidney Cancer Medicine Growth Trends by Region
2.2.1 Global Kidney Cancer Medicine Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Kidney Cancer Medicine Historic Market Size by Region (2020-2025)
2.2.3 Kidney Cancer Medicine Forecasted Market Size by Region (2026-2031)
2.3 Kidney Cancer Medicine Market Dynamics
2.3.1 Kidney Cancer Medicine Industry Trends
2.3.2 Kidney Cancer Medicine Market Drivers
2.3.3 Kidney Cancer Medicine Market Challenges
2.3.4 Kidney Cancer Medicine Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Kidney Cancer Medicine Players by Revenue
3.1.1 Global Top Kidney Cancer Medicine Players by Revenue (2020-2025)
3.1.2 Global Kidney Cancer Medicine Revenue Market Share by Players (2020-2025)
3.2 Global Kidney Cancer Medicine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Kidney Cancer Medicine Revenue
3.4 Global Kidney Cancer Medicine Market Concentration Ratio
3.4.1 Global Kidney Cancer Medicine Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Kidney Cancer Medicine Revenue in 2024
3.5 Global Key Players of Kidney Cancer Medicine Head office and Area Served
3.6 Global Key Players of Kidney Cancer Medicine, Product and Application
3.7 Global Key Players of Kidney Cancer Medicine, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Kidney Cancer Medicine Breakdown Data by Type
4.1 Global Kidney Cancer Medicine Historic Market Size by Type (2020-2025)
4.2 Global Kidney Cancer Medicine Forecasted Market Size by Type (2026-2031)
5 Kidney Cancer Medicine Breakdown Data by Application
5.1 Global Kidney Cancer Medicine Historic Market Size by Application (2020-2025)
5.2 Global Kidney Cancer Medicine Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Kidney Cancer Medicine Market Size (2020-2031)
6.2 North America Kidney Cancer Medicine Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Kidney Cancer Medicine Market Size by Country (2020-2025)
6.4 North America Kidney Cancer Medicine Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Kidney Cancer Medicine Market Size (2020-2031)
7.2 Europe Kidney Cancer Medicine Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Kidney Cancer Medicine Market Size by Country (2020-2025)
7.4 Europe Kidney Cancer Medicine Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Kidney Cancer Medicine Market Size (2020-2031)
8.2 Asia-Pacific Kidney Cancer Medicine Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Kidney Cancer Medicine Market Size by Region (2020-2025)
8.4 Asia-Pacific Kidney Cancer Medicine Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Kidney Cancer Medicine Market Size (2020-2031)
9.2 Latin America Kidney Cancer Medicine Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Kidney Cancer Medicine Market Size by Country (2020-2025)
9.4 Latin America Kidney Cancer Medicine Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Kidney Cancer Medicine Market Size (2020-2031)
10.2 Middle East & Africa Kidney Cancer Medicine Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Kidney Cancer Medicine Market Size by Country (2020-2025)
10.4 Middle East & Africa Kidney Cancer Medicine Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Pfizer
11.1.1 Pfizer Company Details
11.1.2 Pfizer Business Overview
11.1.3 Pfizer Kidney Cancer Medicine Introduction
11.1.4 Pfizer Revenue in Kidney Cancer Medicine Business (2020-2025)
11.1.5 Pfizer Recent Development
11.2 Bristol-Myers Squibb
11.2.1 Bristol-Myers Squibb Company Details
11.2.2 Bristol-Myers Squibb Business Overview
11.2.3 Bristol-Myers Squibb Kidney Cancer Medicine Introduction
11.2.4 Bristol-Myers Squibb Revenue in Kidney Cancer Medicine Business (2020-2025)
11.2.5 Bristol-Myers Squibb Recent Development
11.3 Roche
11.3.1 Roche Company Details
11.3.2 Roche Business Overview
11.3.3 Roche Kidney Cancer Medicine Introduction
11.3.4 Roche Revenue in Kidney Cancer Medicine Business (2020-2025)
11.3.5 Roche Recent Development
11.4 GSK
11.4.1 GSK Company Details
11.4.2 GSK Business Overview
11.4.3 GSK Kidney Cancer Medicine Introduction
11.4.4 GSK Revenue in Kidney Cancer Medicine Business (2020-2025)
11.4.5 GSK Recent Development
11.5 Novartis
11.5.1 Novartis Company Details
11.5.2 Novartis Business Overview
11.5.3 Novartis Kidney Cancer Medicine Introduction
11.5.4 Novartis Revenue in Kidney Cancer Medicine Business (2020-2025)
11.5.5 Novartis Recent Development
11.6 Bayer
11.6.1 Bayer Company Details
11.6.2 Bayer Business Overview
11.6.3 Bayer Kidney Cancer Medicine Introduction
11.6.4 Bayer Revenue in Kidney Cancer Medicine Business (2020-2025)
11.6.5 Bayer Recent Development
11.7 Merck & Co.
11.7.1 Merck & Co. Company Details
11.7.2 Merck & Co. Business Overview
11.7.3 Merck & Co. Kidney Cancer Medicine Introduction
11.7.4 Merck & Co. Revenue in Kidney Cancer Medicine Business (2020-2025)
11.7.5 Merck & Co. Recent Development
11.8 Exelixis
11.8.1 Exelixis Company Details
11.8.2 Exelixis Business Overview
11.8.3 Exelixis Kidney Cancer Medicine Introduction
11.8.4 Exelixis Revenue in Kidney Cancer Medicine Business (2020-2025)
11.8.5 Exelixis Recent Development
11.9 Takeda
11.9.1 Takeda Company Details
11.9.2 Takeda Business Overview
11.9.3 Takeda Kidney Cancer Medicine Introduction
11.9.4 Takeda Revenue in Kidney Cancer Medicine Business (2020-2025)
11.9.5 Takeda Recent Development
11.10 Eisai
11.10.1 Eisai Company Details
11.10.2 Eisai Business Overview
11.10.3 Eisai Kidney Cancer Medicine Introduction
11.10.4 Eisai Revenue in Kidney Cancer Medicine Business (2020-2025)
11.10.5 Eisai Recent Development
11.11 CTTQ
11.11.1 CTTQ Company Details
11.11.2 CTTQ Business Overview
11.11.3 CTTQ Kidney Cancer Medicine Introduction
11.11.4 CTTQ Revenue in Kidney Cancer Medicine Business (2020-2025)
11.11.5 CTTQ Recent Development
11.12 AVEO Oncology
11.12.1 AVEO Oncology Company Details
11.12.2 AVEO Oncology Business Overview
11.12.3 AVEO Oncology Kidney Cancer Medicine Introduction
11.12.4 AVEO Oncology Revenue in Kidney Cancer Medicine Business (2020-2025)
11.12.5 AVEO Oncology Recent Development
11.13 Everest Pharm
11.13.1 Everest Pharm Company Details
11.13.2 Everest Pharm Business Overview
11.13.3 Everest Pharm Kidney Cancer Medicine Introduction
11.13.4 Everest Pharm Revenue in Kidney Cancer Medicine Business (2020-2025)
11.13.5 Everest Pharm Recent Development
11.14 Cipla
11.14.1 Cipla Company Details
11.14.2 Cipla Business Overview
11.14.3 Cipla Kidney Cancer Medicine Introduction
11.14.4 Cipla Revenue in Kidney Cancer Medicine Business (2020-2025)
11.14.5 Cipla Recent Development
11.15 NATCO
11.15.1 NATCO Company Details
11.15.2 NATCO Business Overview
11.15.3 NATCO Kidney Cancer Medicine Introduction
11.15.4 NATCO Revenue in Kidney Cancer Medicine Business (2020-2025)
11.15.5 NATCO Recent Development
11.16 Beacon Pharma
11.16.1 Beacon Pharma Company Details
11.16.2 Beacon Pharma Business Overview
11.16.3 Beacon Pharma Kidney Cancer Medicine Introduction
11.16.4 Beacon Pharma Revenue in Kidney Cancer Medicine Business (2020-2025)
11.16.5 Beacon Pharma Recent Development
11.17 SAMARTH
11.17.1 SAMARTH Company Details
11.17.2 SAMARTH Business Overview
11.17.3 SAMARTH Kidney Cancer Medicine Introduction
11.17.4 SAMARTH Revenue in Kidney Cancer Medicine Business (2020-2025)
11.17.5 SAMARTH Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Kidney Cancer Medicine Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Monoclonal Antibody
Table 3. Key Players of mTOR Inhibitors
Table 4. Key Players of Kinase Inhibitors
Table 5. Key Players of Other
Table 6. Global Kidney Cancer Medicine Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 7. Global Kidney Cancer Medicine Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 8. Global Kidney Cancer Medicine Market Size by Region (2020-2025) & (US$ Million)
Table 9. Global Kidney Cancer Medicine Market Share by Region (2020-2025)
Table 10. Global Kidney Cancer Medicine Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 11. Global Kidney Cancer Medicine Market Share by Region (2026-2031)
Table 12. Kidney Cancer Medicine Market Trends
Table 13. Kidney Cancer Medicine Market Drivers
Table 14. Kidney Cancer Medicine Market Challenges
Table 15. Kidney Cancer Medicine Market Restraints
Table 16. Global Kidney Cancer Medicine Revenue by Players (2020-2025) & (US$ Million)
Table 17. Global Kidney Cancer Medicine Market Share by Players (2020-2025)
Table 18. Global Top Kidney Cancer Medicine Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Kidney Cancer Medicine as of 2024)
Table 19. Ranking of Global Top Kidney Cancer Medicine Companies by Revenue (US$ Million) in 2024
Table 20. Global 5 Largest Players Market Share by Kidney Cancer Medicine Revenue (CR5 and HHI) & (2020-2025)
Table 21. Global Key Players of Kidney Cancer Medicine, Headquarters and Area Served
Table 22. Global Key Players of Kidney Cancer Medicine, Product and Application
Table 23. Global Key Players of Kidney Cancer Medicine, Date of Enter into This Industry
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Kidney Cancer Medicine Market Size by Type (2020-2025) & (US$ Million)
Table 26. Global Kidney Cancer Medicine Revenue Market Share by Type (2020-2025)
Table 27. Global Kidney Cancer Medicine Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 28. Global Kidney Cancer Medicine Revenue Market Share by Type (2026-2031)
Table 29. Global Kidney Cancer Medicine Market Size by Application (2020-2025) & (US$ Million)
Table 30. Global Kidney Cancer Medicine Revenue Market Share by Application (2020-2025)
Table 31. Global Kidney Cancer Medicine Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 32. Global Kidney Cancer Medicine Revenue Market Share by Application (2026-2031)
Table 33. North America Kidney Cancer Medicine Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 34. North America Kidney Cancer Medicine Market Size by Country (2020-2025) & (US$ Million)
Table 35. North America Kidney Cancer Medicine Market Size by Country (2026-2031) & (US$ Million)
Table 36. Europe Kidney Cancer Medicine Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 37. Europe Kidney Cancer Medicine Market Size by Country (2020-2025) & (US$ Million)
Table 38. Europe Kidney Cancer Medicine Market Size by Country (2026-2031) & (US$ Million)
Table 39. Asia-Pacific Kidney Cancer Medicine Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 40. Asia-Pacific Kidney Cancer Medicine Market Size by Region (2020-2025) & (US$ Million)
Table 41. Asia-Pacific Kidney Cancer Medicine Market Size by Region (2026-2031) & (US$ Million)
Table 42. Latin America Kidney Cancer Medicine Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 43. Latin America Kidney Cancer Medicine Market Size by Country (2020-2025) & (US$ Million)
Table 44. Latin America Kidney Cancer Medicine Market Size by Country (2026-2031) & (US$ Million)
Table 45. Middle East & Africa Kidney Cancer Medicine Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 46. Middle East & Africa Kidney Cancer Medicine Market Size by Country (2020-2025) & (US$ Million)
Table 47. Middle East & Africa Kidney Cancer Medicine Market Size by Country (2026-2031) & (US$ Million)
Table 48. Pfizer Company Details
Table 49. Pfizer Business Overview
Table 50. Pfizer Kidney Cancer Medicine Product
Table 51. Pfizer Revenue in Kidney Cancer Medicine Business (2020-2025) & (US$ Million)
Table 52. Pfizer Recent Development
Table 53. Bristol-Myers Squibb Company Details
Table 54. Bristol-Myers Squibb Business Overview
Table 55. Bristol-Myers Squibb Kidney Cancer Medicine Product
Table 56. Bristol-Myers Squibb Revenue in Kidney Cancer Medicine Business (2020-2025) & (US$ Million)
Table 57. Bristol-Myers Squibb Recent Development
Table 58. Roche Company Details
Table 59. Roche Business Overview
Table 60. Roche Kidney Cancer Medicine Product
Table 61. Roche Revenue in Kidney Cancer Medicine Business (2020-2025) & (US$ Million)
Table 62. Roche Recent Development
Table 63. GSK Company Details
Table 64. GSK Business Overview
Table 65. GSK Kidney Cancer Medicine Product
Table 66. GSK Revenue in Kidney Cancer Medicine Business (2020-2025) & (US$ Million)
Table 67. GSK Recent Development
Table 68. Novartis Company Details
Table 69. Novartis Business Overview
Table 70. Novartis Kidney Cancer Medicine Product
Table 71. Novartis Revenue in Kidney Cancer Medicine Business (2020-2025) & (US$ Million)
Table 72. Novartis Recent Development
Table 73. Bayer Company Details
Table 74. Bayer Business Overview
Table 75. Bayer Kidney Cancer Medicine Product
Table 76. Bayer Revenue in Kidney Cancer Medicine Business (2020-2025) & (US$ Million)
Table 77. Bayer Recent Development
Table 78. Merck & Co. Company Details
Table 79. Merck & Co. Business Overview
Table 80. Merck & Co. Kidney Cancer Medicine Product
Table 81. Merck & Co. Revenue in Kidney Cancer Medicine Business (2020-2025) & (US$ Million)
Table 82. Merck & Co. Recent Development
Table 83. Exelixis Company Details
Table 84. Exelixis Business Overview
Table 85. Exelixis Kidney Cancer Medicine Product
Table 86. Exelixis Revenue in Kidney Cancer Medicine Business (2020-2025) & (US$ Million)
Table 87. Exelixis Recent Development
Table 88. Takeda Company Details
Table 89. Takeda Business Overview
Table 90. Takeda Kidney Cancer Medicine Product
Table 91. Takeda Revenue in Kidney Cancer Medicine Business (2020-2025) & (US$ Million)
Table 92. Takeda Recent Development
Table 93. Eisai Company Details
Table 94. Eisai Business Overview
Table 95. Eisai Kidney Cancer Medicine Product
Table 96. Eisai Revenue in Kidney Cancer Medicine Business (2020-2025) & (US$ Million)
Table 97. Eisai Recent Development
Table 98. CTTQ Company Details
Table 99. CTTQ Business Overview
Table 100. CTTQ Kidney Cancer Medicine Product
Table 101. CTTQ Revenue in Kidney Cancer Medicine Business (2020-2025) & (US$ Million)
Table 102. CTTQ Recent Development
Table 103. AVEO Oncology Company Details
Table 104. AVEO Oncology Business Overview
Table 105. AVEO Oncology Kidney Cancer Medicine Product
Table 106. AVEO Oncology Revenue in Kidney Cancer Medicine Business (2020-2025) & (US$ Million)
Table 107. AVEO Oncology Recent Development
Table 108. Everest Pharm Company Details
Table 109. Everest Pharm Business Overview
Table 110. Everest Pharm Kidney Cancer Medicine Product
Table 111. Everest Pharm Revenue in Kidney Cancer Medicine Business (2020-2025) & (US$ Million)
Table 112. Everest Pharm Recent Development
Table 113. Cipla Company Details
Table 114. Cipla Business Overview
Table 115. Cipla Kidney Cancer Medicine Product
Table 116. Cipla Revenue in Kidney Cancer Medicine Business (2020-2025) & (US$ Million)
Table 117. Cipla Recent Development
Table 118. NATCO Company Details
Table 119. NATCO Business Overview
Table 120. NATCO Kidney Cancer Medicine Product
Table 121. NATCO Revenue in Kidney Cancer Medicine Business (2020-2025) & (US$ Million)
Table 122. NATCO Recent Development
Table 123. Beacon Pharma Company Details
Table 124. Beacon Pharma Business Overview
Table 125. Beacon Pharma Kidney Cancer Medicine Product
Table 126. Beacon Pharma Revenue in Kidney Cancer Medicine Business (2020-2025) & (US$ Million)
Table 127. Beacon Pharma Recent Development
Table 128. SAMARTH Company Details
Table 129. SAMARTH Business Overview
Table 130. SAMARTH Kidney Cancer Medicine Product
Table 131. SAMARTH Revenue in Kidney Cancer Medicine Business (2020-2025) & (US$ Million)
Table 132. SAMARTH Recent Development
Table 133. Research Programs/Design for This Report
Table 134. Key Data Information from Secondary Sources
Table 135. Key Data Information from Primary Sources
Table 136. Authors List of This Report
List of Figures
Figure 1. Kidney Cancer Medicine Picture
Figure 2. Global Kidney Cancer Medicine Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Kidney Cancer Medicine Market Share by Type: 2024 VS 2031
Figure 4. Monoclonal Antibody Features
Figure 5. mTOR Inhibitors Features
Figure 6. Kinase Inhibitors Features
Figure 7. Other Features
Figure 8. Global Kidney Cancer Medicine Market Size by Application (2020-2031) & (US$ Million)
Figure 9. Global Kidney Cancer Medicine Market Share by Application: 2024 VS 2031
Figure 10. Renal Cell Carcinoma (RCC) Case Studies
Figure 11. Transitional Cell Carcinoma (TCC) Case Studies
Figure 12. Kidney Cancer Medicine Report Years Considered
Figure 13. Global Kidney Cancer Medicine Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 14. Global Kidney Cancer Medicine Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 15. Global Kidney Cancer Medicine Market Share by Region: 2024 VS 2031
Figure 16. Global Kidney Cancer Medicine Market Share by Players in 2024
Figure 17. Global Top Kidney Cancer Medicine Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Kidney Cancer Medicine as of 2024)
Figure 18. The Top 10 and 5 Players Market Share by Kidney Cancer Medicine Revenue in 2024
Figure 19. North America Kidney Cancer Medicine Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 20. North America Kidney Cancer Medicine Market Share by Country (2020-2031)
Figure 21. United States Kidney Cancer Medicine Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 22. Canada Kidney Cancer Medicine Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 23. Europe Kidney Cancer Medicine Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 24. Europe Kidney Cancer Medicine Market Share by Country (2020-2031)
Figure 25. Germany Kidney Cancer Medicine Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. France Kidney Cancer Medicine Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. U.K. Kidney Cancer Medicine Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. Italy Kidney Cancer Medicine Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Russia Kidney Cancer Medicine Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Nordic Countries Kidney Cancer Medicine Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Asia-Pacific Kidney Cancer Medicine Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Asia-Pacific Kidney Cancer Medicine Market Share by Region (2020-2031)
Figure 33. China Kidney Cancer Medicine Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. Japan Kidney Cancer Medicine Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. South Korea Kidney Cancer Medicine Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. Southeast Asia Kidney Cancer Medicine Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. India Kidney Cancer Medicine Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. Australia Kidney Cancer Medicine Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Latin America Kidney Cancer Medicine Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Latin America Kidney Cancer Medicine Market Share by Country (2020-2031)
Figure 41. Mexico Kidney Cancer Medicine Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Brazil Kidney Cancer Medicine Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Middle East & Africa Kidney Cancer Medicine Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Middle East & Africa Kidney Cancer Medicine Market Share by Country (2020-2031)
Figure 45. Turkey Kidney Cancer Medicine Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. Saudi Arabia Kidney Cancer Medicine Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. UAE Kidney Cancer Medicine Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. Pfizer Revenue Growth Rate in Kidney Cancer Medicine Business (2020-2025)
Figure 49. Bristol-Myers Squibb Revenue Growth Rate in Kidney Cancer Medicine Business (2020-2025)
Figure 50. Roche Revenue Growth Rate in Kidney Cancer Medicine Business (2020-2025)
Figure 51. GSK Revenue Growth Rate in Kidney Cancer Medicine Business (2020-2025)
Figure 52. Novartis Revenue Growth Rate in Kidney Cancer Medicine Business (2020-2025)
Figure 53. Bayer Revenue Growth Rate in Kidney Cancer Medicine Business (2020-2025)
Figure 54. Merck & Co. Revenue Growth Rate in Kidney Cancer Medicine Business (2020-2025)
Figure 55. Exelixis Revenue Growth Rate in Kidney Cancer Medicine Business (2020-2025)
Figure 56. Takeda Revenue Growth Rate in Kidney Cancer Medicine Business (2020-2025)
Figure 57. Eisai Revenue Growth Rate in Kidney Cancer Medicine Business (2020-2025)
Figure 58. CTTQ Revenue Growth Rate in Kidney Cancer Medicine Business (2020-2025)
Figure 59. AVEO Oncology Revenue Growth Rate in Kidney Cancer Medicine Business (2020-2025)
Figure 60. Everest Pharm Revenue Growth Rate in Kidney Cancer Medicine Business (2020-2025)
Figure 61. Cipla Revenue Growth Rate in Kidney Cancer Medicine Business (2020-2025)
Figure 62. NATCO Revenue Growth Rate in Kidney Cancer Medicine Business (2020-2025)
Figure 63. Beacon Pharma Revenue Growth Rate in Kidney Cancer Medicine Business (2020-2025)
Figure 64. SAMARTH Revenue Growth Rate in Kidney Cancer Medicine Business (2020-2025)
Figure 65. Bottom-up and Top-down Approaches for This Report
Figure 66. Data Triangulation
Figure 67. Key Executives Interviewed
Table 1. Global Kidney Cancer Medicine Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Monoclonal Antibody
Table 3. Key Players of mTOR Inhibitors
Table 4. Key Players of Kinase Inhibitors
Table 5. Key Players of Other
Table 6. Global Kidney Cancer Medicine Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 7. Global Kidney Cancer Medicine Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 8. Global Kidney Cancer Medicine Market Size by Region (2020-2025) & (US$ Million)
Table 9. Global Kidney Cancer Medicine Market Share by Region (2020-2025)
Table 10. Global Kidney Cancer Medicine Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 11. Global Kidney Cancer Medicine Market Share by Region (2026-2031)
Table 12. Kidney Cancer Medicine Market Trends
Table 13. Kidney Cancer Medicine Market Drivers
Table 14. Kidney Cancer Medicine Market Challenges
Table 15. Kidney Cancer Medicine Market Restraints
Table 16. Global Kidney Cancer Medicine Revenue by Players (2020-2025) & (US$ Million)
Table 17. Global Kidney Cancer Medicine Market Share by Players (2020-2025)
Table 18. Global Top Kidney Cancer Medicine Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Kidney Cancer Medicine as of 2024)
Table 19. Ranking of Global Top Kidney Cancer Medicine Companies by Revenue (US$ Million) in 2024
Table 20. Global 5 Largest Players Market Share by Kidney Cancer Medicine Revenue (CR5 and HHI) & (2020-2025)
Table 21. Global Key Players of Kidney Cancer Medicine, Headquarters and Area Served
Table 22. Global Key Players of Kidney Cancer Medicine, Product and Application
Table 23. Global Key Players of Kidney Cancer Medicine, Date of Enter into This Industry
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Kidney Cancer Medicine Market Size by Type (2020-2025) & (US$ Million)
Table 26. Global Kidney Cancer Medicine Revenue Market Share by Type (2020-2025)
Table 27. Global Kidney Cancer Medicine Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 28. Global Kidney Cancer Medicine Revenue Market Share by Type (2026-2031)
Table 29. Global Kidney Cancer Medicine Market Size by Application (2020-2025) & (US$ Million)
Table 30. Global Kidney Cancer Medicine Revenue Market Share by Application (2020-2025)
Table 31. Global Kidney Cancer Medicine Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 32. Global Kidney Cancer Medicine Revenue Market Share by Application (2026-2031)
Table 33. North America Kidney Cancer Medicine Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 34. North America Kidney Cancer Medicine Market Size by Country (2020-2025) & (US$ Million)
Table 35. North America Kidney Cancer Medicine Market Size by Country (2026-2031) & (US$ Million)
Table 36. Europe Kidney Cancer Medicine Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 37. Europe Kidney Cancer Medicine Market Size by Country (2020-2025) & (US$ Million)
Table 38. Europe Kidney Cancer Medicine Market Size by Country (2026-2031) & (US$ Million)
Table 39. Asia-Pacific Kidney Cancer Medicine Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 40. Asia-Pacific Kidney Cancer Medicine Market Size by Region (2020-2025) & (US$ Million)
Table 41. Asia-Pacific Kidney Cancer Medicine Market Size by Region (2026-2031) & (US$ Million)
Table 42. Latin America Kidney Cancer Medicine Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 43. Latin America Kidney Cancer Medicine Market Size by Country (2020-2025) & (US$ Million)
Table 44. Latin America Kidney Cancer Medicine Market Size by Country (2026-2031) & (US$ Million)
Table 45. Middle East & Africa Kidney Cancer Medicine Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 46. Middle East & Africa Kidney Cancer Medicine Market Size by Country (2020-2025) & (US$ Million)
Table 47. Middle East & Africa Kidney Cancer Medicine Market Size by Country (2026-2031) & (US$ Million)
Table 48. Pfizer Company Details
Table 49. Pfizer Business Overview
Table 50. Pfizer Kidney Cancer Medicine Product
Table 51. Pfizer Revenue in Kidney Cancer Medicine Business (2020-2025) & (US$ Million)
Table 52. Pfizer Recent Development
Table 53. Bristol-Myers Squibb Company Details
Table 54. Bristol-Myers Squibb Business Overview
Table 55. Bristol-Myers Squibb Kidney Cancer Medicine Product
Table 56. Bristol-Myers Squibb Revenue in Kidney Cancer Medicine Business (2020-2025) & (US$ Million)
Table 57. Bristol-Myers Squibb Recent Development
Table 58. Roche Company Details
Table 59. Roche Business Overview
Table 60. Roche Kidney Cancer Medicine Product
Table 61. Roche Revenue in Kidney Cancer Medicine Business (2020-2025) & (US$ Million)
Table 62. Roche Recent Development
Table 63. GSK Company Details
Table 64. GSK Business Overview
Table 65. GSK Kidney Cancer Medicine Product
Table 66. GSK Revenue in Kidney Cancer Medicine Business (2020-2025) & (US$ Million)
Table 67. GSK Recent Development
Table 68. Novartis Company Details
Table 69. Novartis Business Overview
Table 70. Novartis Kidney Cancer Medicine Product
Table 71. Novartis Revenue in Kidney Cancer Medicine Business (2020-2025) & (US$ Million)
Table 72. Novartis Recent Development
Table 73. Bayer Company Details
Table 74. Bayer Business Overview
Table 75. Bayer Kidney Cancer Medicine Product
Table 76. Bayer Revenue in Kidney Cancer Medicine Business (2020-2025) & (US$ Million)
Table 77. Bayer Recent Development
Table 78. Merck & Co. Company Details
Table 79. Merck & Co. Business Overview
Table 80. Merck & Co. Kidney Cancer Medicine Product
Table 81. Merck & Co. Revenue in Kidney Cancer Medicine Business (2020-2025) & (US$ Million)
Table 82. Merck & Co. Recent Development
Table 83. Exelixis Company Details
Table 84. Exelixis Business Overview
Table 85. Exelixis Kidney Cancer Medicine Product
Table 86. Exelixis Revenue in Kidney Cancer Medicine Business (2020-2025) & (US$ Million)
Table 87. Exelixis Recent Development
Table 88. Takeda Company Details
Table 89. Takeda Business Overview
Table 90. Takeda Kidney Cancer Medicine Product
Table 91. Takeda Revenue in Kidney Cancer Medicine Business (2020-2025) & (US$ Million)
Table 92. Takeda Recent Development
Table 93. Eisai Company Details
Table 94. Eisai Business Overview
Table 95. Eisai Kidney Cancer Medicine Product
Table 96. Eisai Revenue in Kidney Cancer Medicine Business (2020-2025) & (US$ Million)
Table 97. Eisai Recent Development
Table 98. CTTQ Company Details
Table 99. CTTQ Business Overview
Table 100. CTTQ Kidney Cancer Medicine Product
Table 101. CTTQ Revenue in Kidney Cancer Medicine Business (2020-2025) & (US$ Million)
Table 102. CTTQ Recent Development
Table 103. AVEO Oncology Company Details
Table 104. AVEO Oncology Business Overview
Table 105. AVEO Oncology Kidney Cancer Medicine Product
Table 106. AVEO Oncology Revenue in Kidney Cancer Medicine Business (2020-2025) & (US$ Million)
Table 107. AVEO Oncology Recent Development
Table 108. Everest Pharm Company Details
Table 109. Everest Pharm Business Overview
Table 110. Everest Pharm Kidney Cancer Medicine Product
Table 111. Everest Pharm Revenue in Kidney Cancer Medicine Business (2020-2025) & (US$ Million)
Table 112. Everest Pharm Recent Development
Table 113. Cipla Company Details
Table 114. Cipla Business Overview
Table 115. Cipla Kidney Cancer Medicine Product
Table 116. Cipla Revenue in Kidney Cancer Medicine Business (2020-2025) & (US$ Million)
Table 117. Cipla Recent Development
Table 118. NATCO Company Details
Table 119. NATCO Business Overview
Table 120. NATCO Kidney Cancer Medicine Product
Table 121. NATCO Revenue in Kidney Cancer Medicine Business (2020-2025) & (US$ Million)
Table 122. NATCO Recent Development
Table 123. Beacon Pharma Company Details
Table 124. Beacon Pharma Business Overview
Table 125. Beacon Pharma Kidney Cancer Medicine Product
Table 126. Beacon Pharma Revenue in Kidney Cancer Medicine Business (2020-2025) & (US$ Million)
Table 127. Beacon Pharma Recent Development
Table 128. SAMARTH Company Details
Table 129. SAMARTH Business Overview
Table 130. SAMARTH Kidney Cancer Medicine Product
Table 131. SAMARTH Revenue in Kidney Cancer Medicine Business (2020-2025) & (US$ Million)
Table 132. SAMARTH Recent Development
Table 133. Research Programs/Design for This Report
Table 134. Key Data Information from Secondary Sources
Table 135. Key Data Information from Primary Sources
Table 136. Authors List of This Report
List of Figures
Figure 1. Kidney Cancer Medicine Picture
Figure 2. Global Kidney Cancer Medicine Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Kidney Cancer Medicine Market Share by Type: 2024 VS 2031
Figure 4. Monoclonal Antibody Features
Figure 5. mTOR Inhibitors Features
Figure 6. Kinase Inhibitors Features
Figure 7. Other Features
Figure 8. Global Kidney Cancer Medicine Market Size by Application (2020-2031) & (US$ Million)
Figure 9. Global Kidney Cancer Medicine Market Share by Application: 2024 VS 2031
Figure 10. Renal Cell Carcinoma (RCC) Case Studies
Figure 11. Transitional Cell Carcinoma (TCC) Case Studies
Figure 12. Kidney Cancer Medicine Report Years Considered
Figure 13. Global Kidney Cancer Medicine Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 14. Global Kidney Cancer Medicine Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 15. Global Kidney Cancer Medicine Market Share by Region: 2024 VS 2031
Figure 16. Global Kidney Cancer Medicine Market Share by Players in 2024
Figure 17. Global Top Kidney Cancer Medicine Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Kidney Cancer Medicine as of 2024)
Figure 18. The Top 10 and 5 Players Market Share by Kidney Cancer Medicine Revenue in 2024
Figure 19. North America Kidney Cancer Medicine Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 20. North America Kidney Cancer Medicine Market Share by Country (2020-2031)
Figure 21. United States Kidney Cancer Medicine Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 22. Canada Kidney Cancer Medicine Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 23. Europe Kidney Cancer Medicine Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 24. Europe Kidney Cancer Medicine Market Share by Country (2020-2031)
Figure 25. Germany Kidney Cancer Medicine Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. France Kidney Cancer Medicine Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. U.K. Kidney Cancer Medicine Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. Italy Kidney Cancer Medicine Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Russia Kidney Cancer Medicine Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Nordic Countries Kidney Cancer Medicine Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Asia-Pacific Kidney Cancer Medicine Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Asia-Pacific Kidney Cancer Medicine Market Share by Region (2020-2031)
Figure 33. China Kidney Cancer Medicine Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. Japan Kidney Cancer Medicine Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. South Korea Kidney Cancer Medicine Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. Southeast Asia Kidney Cancer Medicine Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. India Kidney Cancer Medicine Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. Australia Kidney Cancer Medicine Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Latin America Kidney Cancer Medicine Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Latin America Kidney Cancer Medicine Market Share by Country (2020-2031)
Figure 41. Mexico Kidney Cancer Medicine Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Brazil Kidney Cancer Medicine Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Middle East & Africa Kidney Cancer Medicine Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Middle East & Africa Kidney Cancer Medicine Market Share by Country (2020-2031)
Figure 45. Turkey Kidney Cancer Medicine Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. Saudi Arabia Kidney Cancer Medicine Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. UAE Kidney Cancer Medicine Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. Pfizer Revenue Growth Rate in Kidney Cancer Medicine Business (2020-2025)
Figure 49. Bristol-Myers Squibb Revenue Growth Rate in Kidney Cancer Medicine Business (2020-2025)
Figure 50. Roche Revenue Growth Rate in Kidney Cancer Medicine Business (2020-2025)
Figure 51. GSK Revenue Growth Rate in Kidney Cancer Medicine Business (2020-2025)
Figure 52. Novartis Revenue Growth Rate in Kidney Cancer Medicine Business (2020-2025)
Figure 53. Bayer Revenue Growth Rate in Kidney Cancer Medicine Business (2020-2025)
Figure 54. Merck & Co. Revenue Growth Rate in Kidney Cancer Medicine Business (2020-2025)
Figure 55. Exelixis Revenue Growth Rate in Kidney Cancer Medicine Business (2020-2025)
Figure 56. Takeda Revenue Growth Rate in Kidney Cancer Medicine Business (2020-2025)
Figure 57. Eisai Revenue Growth Rate in Kidney Cancer Medicine Business (2020-2025)
Figure 58. CTTQ Revenue Growth Rate in Kidney Cancer Medicine Business (2020-2025)
Figure 59. AVEO Oncology Revenue Growth Rate in Kidney Cancer Medicine Business (2020-2025)
Figure 60. Everest Pharm Revenue Growth Rate in Kidney Cancer Medicine Business (2020-2025)
Figure 61. Cipla Revenue Growth Rate in Kidney Cancer Medicine Business (2020-2025)
Figure 62. NATCO Revenue Growth Rate in Kidney Cancer Medicine Business (2020-2025)
Figure 63. Beacon Pharma Revenue Growth Rate in Kidney Cancer Medicine Business (2020-2025)
Figure 64. SAMARTH Revenue Growth Rate in Kidney Cancer Medicine Business (2020-2025)
Figure 65. Bottom-up and Top-down Approaches for This Report
Figure 66. Data Triangulation
Figure 67. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Benzyltrimethylammonium Hydroxide (BTMAH) Market Research Report 2025
Jul 10, 25
Global Allyltrimethylammonium Chloride Market Research Report 2025
Jul 10, 25
Global Calcium Bisglycinate Market Research Report 2025
Jul 10, 25
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232